# HITI earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/HITI) · [Earnings tab](https://www.lopjlb.com/stock/HITI?tab=earnings) Updated: 2026-09-17T06:01:43 Quarters analyzed: 8 ## Cross-quarter narrative High Tide's trajectory shows consistent execution on store expansion and loyalty growth, punctuated by strategic German market entry via Remexian. From 2024 Q3 to 2026 Q2, revenue scaled from record quarterly levels to a $600M run rate, with brick-and-mortar margins improving sequentially while e-commerce remained a drag. The Cabana Club membership and ELITE tier grew steadily, supporting same-store sales gains. Free cash flow positivity persisted across six+ quarters, funding organic growth and acquisitions (Purecan, Remexian, Northern Helm). However, regulatory headwinds shifted: Canadian provincial cap expansions (Ontario, BC) stalled, German medical cannabis law changes loom, and import permit delays disrupted supply chains. Portugal biomass processing issues created temporary margin pressure. E-commerce underperformance persisted since a December 2024 model change, now flagged for potential partnership or sale. Same-store sales growth decelerated in 2026 Q2 amid macro pressure and illicit competition. Management tone remained confident (0.7-0.85) but uncertainty ticked up in 2026 Q1 (0.60) due to weather and regulatory unknowns. The company maintains a shareholder-first capital approach with low leverage (1.5x pro forma EBITDA) and eyes UK entry. ## Latest CallCard · Q2 High Tide posted record Q2 revenue and margins, driven by Remexian’s surge and expanding Cabana Club, while noting same‑store sales lag and uncertainty around Ontario/BC cap expansions and German pricing pressure. **Guidance:** maintained — Management maintains its target of 350 stores and plans to add 20‑30 stores this year, while leaving room to increase the target if caps are raised. **Tone:** mgmt 0.8 · Q&A pressure 0.6 · divergence 0.4 Management highlighted best‑ever Q2 results, all‑time revenue and margin records, and rapid growth in Remexian and loyalty programs. ### Demand visibility Strong demand in German medical cannabis and Canadian market share growth, but same‑store sales underperformed. German market share rose to 14.1% from 6.5%, Canadian cannabis now 53% of German imports, yet same‑store sales lag peers despite higher average store revenue. ### Margins / costs Gross profit margin rose to 27% overall, with Remexian achieving 27% versus 12% in Q1. Consolidated gross profit margin hit an eight‑quarter high of 27%, up over 200 bps sequentially; Remexian gross margin jumped from 12% to 27% year‑over‑year. ### Capital allocation Invested CAD 4.3 M in working capital and announced acquisition of four Northern Helm stores to reach 350‑store target. Quarterly working capital outlay of CAD 4.3 M was the largest in six years; announced agreement to acquire four Northern Helm stores generating CAD 8.5 M revenue and CAD 1.7 M adjusted EBITDA. ### Milestones - **Remexian transaction** [delivered]: Closed Sep 2 2025; Q2 revenue CAD 31.6 M, gross margin 27%. - **German market share increase** [on_track]: Market share up to 14.1% from 6.5% in two quarters. - **Cabana Club membership growth** [on_track]: 2.65 M members, up 39% YoY; goal 3 M members. - **Northern Helm acquisition** [new]: Agreement announced, closing soon, adds four strong‑performing stores. - **Store expansion 2026** [on_track]: Target to add 20‑30 stores this year; currently at 10 new stores announced. - **U.S. e‑commerce stabilization** [on_track]: Adjusted EBITDA improved for the quarter. - **ELITE membership growth** [on_track]: 178 k members, up 84% YoY. - **Canadian imports to Germany** [on_track]: Canada now supplies 53% of German medical cannabis imports, annualized >CAD 400 M. ### Fears / risks - **Regulatory**: Potential limits on Ontario and BC store caps could constrain expansion. - **Pricing pressure**: German market price compression could erode margins despite supply advantages. - **Illicit competition**: High illicit market share in BC threatens legal sales growth. - **Macro-economic**: Consumer wallets under pressure, contributing to same‑store sales underperformance. - **Supply chain timing**: German business relies on timing of bulk shipments, adding volatility. - **Competitive landscape**: Other Canadian firms entering Germany increase competitive pressure. - **Market share risk**: Maintaining 14.1% market share in Germany may be challenging. - **Working capital volatility**: Large quarterly working capital investment could affect free cash flow. ### Key quotes > “I am extremely proud to report that not only was this our best Q2 ever, but looking at the financial highlights, it was the best overall quarter we have ever reported to our shareholders.” > “Our consolidated gross profit margin set an eight-quarter high and was up over 200 basis points sequentially.” > “The Remexian transaction closed on September 2nd, 2025, and we have used our unparalleled ability to procure cannabis from Canada to boost the company's results, just like we said we would.” > “We are hearing that the government may consider to raise the cap from 150 stores in Ontario to 300 stores. Obviously, that would again mean an exponential opportunity for High Tide.” — Raj Grover > “When we acquired the business, we said that long-term, we intend to do mid-20s gross margins in Remexian. Well, that day has already arrived, and I couldn't be more excited.” — Raj Grover ## Quarter one-liners - **2026 Q2:** High Tide posted record Q2 revenue and margins, driven by Remexian’s surge and expanding Cabana Club, while noting same‑store sales lag and uncertainty around Ontario/BC cap expansions and German pricing pressure. - **2026 Q1:** High Tide posted a 25% revenue jump to $178.3M, 62% adjusted EBITDA growth and positive free cash flow while expanding stores, scaling its Remexian German business and eyeing UK entry, but faces winter‑storm impacts, import delays and regulatory uncertainty. - **2025 Q4:** — - **2025 Q3:** High Tide posts record Q3 with $600M revenue run rate, 18% YoY brick-and-mortar growth, 7.4% same-store sales, closes Remexian acquisition for 16% German import share, generates $7.7M free cash flow. - **2025 Q2:** High Tide hits 200 stores, 6.2% same-store sales growth, $550M trailing revenue; Germany entry progressing, e-commerce drag but core retail strong. - **2025 Q1:** — - **2024 Q4:** High Tide posted record $522.3M revenue, added 29 stores, delivered six quarters of free cash flow and is expanding its Cabana Club globally while acquiring Purecan, but faces Canadian market slowdown and illicit competition. - **2024 Q3:** High Tide posted record Q3 revenue, expanded to 183 stores and 1.55 M club members, remained free‑cash‑flow positive and highlighted growth opportunities in Canada, Germany and the U.S., while noting competitive and regulatory headwinds. ## Theme arcs - **Store expansion** (improving): Grew from 183 to 200+ stores, targeting 350; Ontario/BC cap approvals now at_risk - **Cabana Club loyalty program** (improving): Membership hit 1.55M then accelerated; ELITE tier growing; Cabanalytics revenue on_track - **German market entry** (improving): Remexian 51% stake delivered at 3.6x EBITDA; 16% import share; integration and LP onboarding on_track - **Brick-and-mortar margins** (improving): Gross margin at all-time high for third sequential quarter; EBITDA margin 8.7% (+1.4pp YoY); wages at 7-quarter low - **E-commerce performance** (deteriorating): Model change Dec 2024 led to 9-month underperformance; at_risk; may require partnership, sale, or slimmed platform - **Free cash flow generation** (stable): Six+ quarters positive; $7.7M in 2025 Q3; funds organic growth and acquisitions - **M&A execution** (improving): Purecan (2024 Q4), Remexian (2025 Q3), Northern Helm (2026 Q2); disciplined multiples - **Regulatory environment** (deteriorating): Ontario/BC cap expansions pending; German medical cannabis law uncertainty; import permit delays - **Supply chain resilience** (deteriorating): Portugal disruption (60-70% slowdown); biomass stuck; import permits delayed ~1 month; normalization expected Nov - **Same-store sales momentum** (deteriorating): 6.2% (2025 Q2) to 7.4% (2025 Q3) then lagged in 2026 Q2 amid macro pressure and illicit competition ## Guidance path 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/HITI`